The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry

Leukemia. 2013 Feb;27(2):507-10. doi: 10.1038/leu.2012.209. Epub 2012 Jul 19.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Biological Assay
  • Drug Monitoring*
  • Drug Resistance, Neoplasm*
  • Follow-Up Studies
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Multicenter Studies as Topic
  • Neoplasm Recurrence, Local / blood
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / mortality
  • Patient Selection*
  • Predictive Value of Tests
  • Prognosis
  • Random Allocation
  • Randomized Controlled Trials as Topic*
  • Survival Rate
  • Vidarabine / analogs & derivatives*
  • Vidarabine / pharmacology

Substances

  • Antineoplastic Agents
  • Vidarabine
  • fludarabine